佰仁医疗(688198.SH)：2025年三季报净利润为9269.69万元

Core Insights - Company Baijun Medical (688198.SH) reported a total revenue of 382 million yuan for Q3 2025, ranking 83rd among disclosed peers [1] - The net profit attributable to shareholders was 92.7 million yuan, with net cash flow from operating activities amounting to 99.9 million yuan [1] Financial Performance - The latest debt-to-asset ratio is 17.09%, which is an increase of 0.31 percentage points from the previous quarter and an increase of 7.82 percentage points year-on-year [3] - The latest gross profit margin is 88.17%, down by 0.38 percentage points from the previous quarter and down by 0.40 percentage points year-on-year [3] - The return on equity (ROE) stands at 7.44% [3] Earnings and Ratios - The diluted earnings per share (EPS) is 0.67 yuan [4] - The total asset turnover ratio is 0.26 times, while the inventory turnover ratio is 0.72 times, ranking 117th among disclosed peers, which is a decrease of 0.06 times year-on-year, reflecting a 7.19% decline [4] Shareholder Structure - The number of shareholders is 3,962, with the top ten shareholders holding 109 million shares, accounting for 79.01% of the total share capital [4] - The largest shareholder, Jinqi, holds 61.05% of the shares [4]